Insider selling: IDEAYA Biosciences (NASDAQ:IDYA) CEO sells 26,338 shares of stock. October 9, 2026 by InsiderTrades.com Key points. * CEO Yujiro Hata sold 26,338 IDEAYA Biosciences shares at an average price of $37.41, generating approximately $985,305; his remaining direct ownership fell 3.67% to 690,695 shares. * IDEAYA shares opened at $36.06, with a market capitalization of about $3.17 billion. The company's latest quarter missed EPS expectations, reporting a loss of $1.22 per share despite revenue of $8.86 million. * Analysts maintain a "Moderate Buy" consensus, with 13 Buy, one Hold and one Sell rating and an average price target of $52.69; institutional investors own 98.29% of the stock. IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of the company's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total transaction of $985,304.58. Following the sale, the chief executive officer directly owned 690,695 shares of the company's stock, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. IDEAYA Biosciences trading down 0.6%. NASDAQ:IDYA opened at $36.06 on Friday. IDEAYA Biosciences, Inc. has a 1 year low of $26.05 and a 1 year high of $42.68. The firm's fifty day simple moving average is $38.13 and its 200 day simple moving average is $34.29. The firm has a market capitalization of $3.17 billion, a PE ratio of -18.59 and a beta of -0.04. IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.06) by ($0.16). The firm had revenue of $8.86 million for the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The firm's revenue was up 8800.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.88) EPS. As a group, analysts anticipate that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current fiscal year. Analyst Ratings changes. Discover more Explore Exchanges Most bought stocks Hire Lawyers A number of research firms have recently commented on IDYA. Guggenheim lifted their price objective on IDEAYA Biosciences from $54.00 to $57.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Weiss Ratings restated a "sell (d-)" rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Citigroup reaffirmed a "market outperform" rating on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Citizens Jmp reiterated a "market outperform" rating and set a $42.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Finally, Truist Financial reduced their price objective on IDEAYA Biosciences from $63.00 to $59.00 and set a "buy" rating for the company in a research report on Wednesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, IDEAYA Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $52.69. Institutional inflows and outflows. A number of large investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in IDEAYA Biosciences during the second quarter worth about $43,000. Nykredit A S bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $76,000. Fifth Third Bancorp bought a new stake in shares of IDEAYA Biosciences in the 1st quarter worth approximately $84,000. GAMMA Investing LLC grew its holdings in shares of IDEAYA Biosciences by 79.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,315 shares of the company's stock worth $89,000 after purchasing an additional 1,022 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of IDEAYA Biosciences by 26.7% during the 2nd quarter. Versant Capital Management Inc now owns 2,825 shares of the company's stock worth $105,000 after purchasing an additional 596 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock. About IDEAYA Biosciences. IDEAYA Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors. Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma. This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected]. Insider Buying or Selling at IDEAYA Biosciences? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for IDEAYA Biosciences and related companies. From Our Partners

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) stock has consensus target price of $52.69. IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has earned an average rating of "Moderate Buy" from the fifteen research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $52.69. IDYA has been the subject of several recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 22nd. Citigroup restated a "market outperform" rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Guggenheim boosted their target price on shares of IDEAYA Biosciences from $54.00 to $57.00 and gave the company a "buy" rating in a research note on Wednesday, September 9th. Wedbush upped their target price on shares of IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Finally, Wall Street Zen cut shares of IDEAYA Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. IDEAYA Biosciences trading down 3.9%. Shares of IDYA opened at $36.58 on Friday. IDEAYA Biosciences has a 1 year low of $26.05 and a 1 year high of $42.68. The stock has a 50 day simple moving average of $38.13 and a 200-day simple moving average of $34.24. The stock has a market cap of $3.21 billion, a PE ratio of -18.85 and a beta of -0.04. IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.16). The company had revenue of $8.86 million during the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. IDEAYA Biosciences's quarterly revenue was up 8800.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.88) EPS. On average, sell-side analysts forecast that IDEAYA Biosciences will post -4.38 EPS for the current fiscal year. Institutional inflows and outflows. A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in IDEAYA Biosciences during the 2nd quarter worth approximately $331,452,000. Jupiter Topco LLC bought a new position in IDEAYA Biosciences in the 2nd quarter valued at $319,728,000. Bank of America Corp DE bought a new position in IDEAYA Biosciences in the 2nd quarter valued at $38,244,000. First Turn Management LLC acquired a new position in IDEAYA Biosciences in the fourth quarter worth $25,017,000. Finally, Fiera Capital Corp boosted its stake in IDEAYA Biosciences by 32.6% in the fourth quarter. Fiera Capital Corp now owns 2,437,262 shares of the company's stock worth $84,256,000 after purchasing an additional 599,295 shares in the last quarter. Institutional investors own 98.29% of the company's stock. IDEAYA Biosciences company profile. IDEAYA Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors. Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma. Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

IDEAYA Biosciences announces the promotion of Dr. Michael White to President, Research and Development. Sep 28, 2026, 06:00 ET SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026. "I am excited to announce this well-deserved promotion for Mike, as President of Research and Development. During Mike's 5-year tenure as Chief Scientific Officer, he has demonstrated exceptional leadership and has been a key driver in advancing IDEAYA's mission to deliver patient impact in areas of high unmet medical need through R&D innovation. Under Mike's leadership, I am excited to see the continued advancement of our industry leading precision medicine oncology pipeline targeting multiple solid tumor indications, including uveal melanoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, among others," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences, Inc. "I am honored to take on this expanded role at such a pivotal time for IDEAYA and grateful for the extraordinary commitment of our research and development teams. We have made tremendous progress in translating our precision medicine capabilities into a deep and differentiated oncology portfolio, with late-stage programs that have the potential to establish new standards of care and early-stage programs that may open entirely new therapeutic opportunities. I am particularly excited by our ability to advance innovative small molecules and antibody-drug conjugates for molecularly defined cancers where patients continue to face significant unmet need. I look forward to building on this momentum and accelerating the delivery of transformative therapies that can meaningfully improve and extend the lives of patients with cancer," said Dr. Michael White, President, Research and Development, IDEAYA Biosciences, Inc. Dr. White has served as Chief Scientific Officer at IDEAYA Biosciences since 2021. Prior to IDEAYA, Dr. White served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc., where he led cross-disciplinary groups in research and development to build an oncology small-molecule clinical pipeline focused on first-in-class therapies, culminating in numerous INDs and late-stage development programs. Prior to joining Pfizer, Dr. White had a prolific over twenty-year academic career at UT Southwestern where he was a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program. In 2015, Dr. White received the inaugural Outstanding Investigator's Award from the National Cancer Institute (NCI), the U.S. Government's principal agency for cancer research, and has authored over 150 publications with over 30,000 citations. Dr. White received his Ph.D. in Biology from the University of North Carolina at Chapel Hill and completed postdoctoral research at Cold Spring Harbor Laboratories in New York. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's research and development strategy and objectives; the expected contributions of Dr. Michael White in his expanded role as President, Research and Development; the continued advancement of IDEAYA's precision medicine oncology pipeline; the potential of IDEAYA's late-stage programs to establish new standards of care and its early-stage programs to create new therapeutic opportunities; IDEAYA's ability to develop and advance innovative small-molecule therapies and antibody-drug conjugates for molecularly defined cancers; and the potential for IDEAYA's product candidates to improve and extend the lives of patients with cancer. These forward-looking statements are based on management's current expectations and assumptions and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to: risks related to the timing, progress, and results of clinical trials and preclinical studies; the ability of IDEAYA to obtain and maintain regulatory approvals; uncertainties regarding the regulatory review process, including participation in the RTOR program; the potential for clinical data to differ from preliminary or interim results; the ability to successfully develop, manufacture, and commercialize product candidates; competition from other biotechnology and pharmaceutical companies; the impact of global economic conditions; IDEAYA's ability to successfully establish, protect and defend its intellectual property: and other risks described in IDEAYA's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements speak only as of the date of this press release, and IDEAYA undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investor and Media Contact IDEAYA Biosciences Joshua Bleharski Chief Financial Officer [email protected] SOURCE IDEAYA Biosciences, Inc.